Sun Pharma's IL-23 inhibitor tildrakizumab gains a psoriatic arthritis indication; the announcement cited no phase 3 efficacy figures.
|Articles|October 1, 2011
- Pharmaceutical Executive-10-01-2011
- Volume 0
- Issue 0
Pharmaceutical Executive Digital Edition - October 2011
Thirty Years of Pharm Exec
Advertisement
Articles in this issue
about 15 years ago
Y. K Hamied : Changing the Dialogueabout 15 years ago
Fred Frank: Fortune and the Financierabout 15 years ago
Marck McLellan: An 'A' for Advancing Expectationsabout 15 years ago
Inside the Mind of the CEO: Steve Collisabout 15 years ago
Atsushi Nagahisa: Creating Customer Valueabout 15 years ago
Physicians: Still the Vital Connection in Medicineabout 15 years ago
Henry Waxman: "Representing" Healthcare to the Fullestabout 15 years ago
IP: Securing a Global Consensus—Can Industry Do It Again?about 15 years ago
In Establishing the Evidence Base, He Made Science Countabout 15 years ago
Jane Henney: Lessons from the FDA Front LineAdvertisement
Related to this article
Brox.AI's co-founder and CEO on why telling an AI to pretend to be a doctor isn’t the same as cloning one — and why that distinction matters for pharma.
Shionogi’s Dr. Draica on why mild COVID-19 still matters, how XOCOVA blocks replication before symptoms, and why prevention beats treatment.
Earlier pediatric planning, innovative trial design, and closer collaboration among regulators, industry, and families are needed to close the persistent gap between the evidence available for adult and pediatric treatments.
BioMarin licenses long-acting Fabry enzyme replacement therapy HM15421/GC1134A, while Ferring agrees to acquire fertility biotech Gameto.
As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
Shionogi’s Dr. Draica on why mild COVID-19 can worsen chronic conditions for up to a year — and why prevention matters more than hospitalization data suggests.
Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion
2
Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial
3
FDA Approves Ilumya for Adults With Active Psoriatic Arthritis
4
Closing the Pediatric Evidence Gap
5